. Ego1
Fenoldopam was infused for a total of 50 min and was stopped just before tumor excision. N o other antihypertensive agents were used. The patient was hydrated aggressively during the procedure with 1 I 5%) albumin, 3 I normal saline, and 1 unit packed erythrocytes to obviate hypotension after tumor removal. Her perioperative urine output was 100 ml/h, with no observed increase during the fenoldopan1 infusion. The patient's renal function remained normal after operation.
Case 2
A 50-pr-old man with a 4-yr history of severe headaches and episodic hypertension and an 8-month history of hot flashes, sweating, antl tachycardia had a blood pressure value of 170/90 mmHg. A computed tomography scan showed a 3 X 5 cm right adrenal mass and incidentally revealed a 5 X 5 cm mass in the left lower renal pole. The urine catecholamine assays (vanillylmandelic acid: 25.3 mg/day, normal: 2-10 mglday; metanephrine: 7.2 mg/day, normal: < 1.3 mg/day; normetanephrine: 6.4 rng/day, normal: < 0.9 mg/day) were consistent with a pheochromocytoma. The results of a workup for Von HippelLindau syndrome were negative. A right adrenalectomy and left nephrectomy were performed after 6 weeks of treatment (phenoxybenzamine, 100 muday).
Anesthesia and monitoring for this patient were similar to those for case 1, with the addition of Dilaudid (Knoll Pharmaceuticals, Whippany, NJ) epidural anesthesia. Under anesthesia, the patient's hemodynamic values were controlled hut varied (MAP, 55-85 mmHg; HR, 55-80 beats/min) until the adrenal mass was manipulated (MAP, 120 mmHg; HR, 68 beats/min). A fenoldopam infusion was begun at 0.2 k g . kg-' . min-' antl rapidly increased to 0. min). Fenoldopam was infused for a total of 100 min. The patient was hydrated aggressively during the procedure with 7 1 normal saline to prevent hypotension after tumor removal. The perioperative urine output was 100 ml/h, with no observed increase during the fenoldopam infusion. After operation, the patient's renal filnction deteriorated slightly, with a peak blood urea nitrogen-creatinine value of 15-2.8 mg/dl, but values returned to normal in 10 days.
Discussion
Fenoldopam causes peripheral vasodilation via selective stimulation of dopamine 1 receptors. It has been compared favorably with nitroprusside in several clinical studies of hypertensive patients.'-5 The activity profile (onset and duration) of fenoldopam would place it well on the list of useful intravenous antihypertensive agents for intraoperative management (table l)." Its short duration of action makes it a desirable agent during pheochrornocytoma resection because of the possibility of hypotension and shock after tumor removal.' Unlike sodium nitroprusside, fenoldopam also increases renal blood flow and can cause diuresis and natriuresis.x.9 Although augmented renal blood flow is a desirable action of this agent, drug-induced diuresis would be undesirable in these patients, because volume expansion is an important part of their treatment."'."
The adverse effects (flushing, hypotension, dizziness, headache, tachycardia) of fenoldopam are related directly to its hernodynamic actions. Compared with nitmprusside, which has toxic metabolites (cyanide, thiocyanate), fenoldopam appears to be a safer drug; when used in combination with nitroprusside, it may help prevent the excessive infusion rates of nitroprusside associated with toxicity.
Our first patient needed only fenoldopam, whereas patient 2 also required sodium nitroprusside and esmolol for blood pressure and HR control. Both of these patients had epinephrine-secreting tumors, but patient 2 was not treated before operation with a beta-blocker. Using fenoldopam allowed us to deAnesthesiology, V 91, N o 2, Aug 1999 crease the amount of sodium nitroprusside needed to control blood pressure in this patient. These two case reports document the successful use of fenoldopam in patients with renal impairment during pheochromocytoma resection. vedled a broken fragment as it was ejected from the heart, and it was retrieved immediately.
Case Report
A 61-yr-old woman with a prosthetic mitral valve who was taking warfarin for anticoagiilation therapy WJS admitted to the hospital after episodes of visual disturbances and slurred speech. Her mitral valve had heen replaced twice: first in 1983 for mitral stenosis, and then 10 yr later for deterioration of the bioprosthetic valve. A 29-mm bileaflet mechanical valve (St. Jude Medical Heart Valve, St. Paul, MN) was implanted at that time and she had received warfarin since then, maintaining an international normalized ratio of 22.5. She also had :itrial fibrillation-flutter, and 2 yr before the current admission had undergone an atrioventricular node ablation and placement of a permanent pacemaker. A TEE was done to evaluate a possible source of embolus as the cause of her current symptoms. The TEE revealed spontaneous echo contrast in the left atrium, a prosthetic mitral valve with normal movement of its leaflets, and a mobile small mass attached Two days later, the patient underwent a mitral valve replacement. She was anesthetized with fentanyl, midazolam, and thiopental, her tracllea was intubaied without complication, Arterial and pulmo. nary artery catheters were placed for hemodynamic monitoring, and TEE (Multiplane TEE probe, Hewlett Packard, Andover, MA) was used during the surgery to evaluate contractility and valve fiinction and to
